newsfilter
← Latest News
Business Wire·

Mirum Pharmaceuticals Completes Enrollment in Phase 3 EXPAND Study of LIVMARLI® (maralixibat) in Additional Rare Cholestatic Liver Diseases

- Study designed to support potential label expansion into additional settings of cholestatic pruritus - Topline data expected in Q4 2026 Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM), a leading rare disease company,